JP2021530536A5 - - Google Patents

Info

Publication number
JP2021530536A5
JP2021530536A5 JP2021502998A JP2021502998A JP2021530536A5 JP 2021530536 A5 JP2021530536 A5 JP 2021530536A5 JP 2021502998 A JP2021502998 A JP 2021502998A JP 2021502998 A JP2021502998 A JP 2021502998A JP 2021530536 A5 JP2021530536 A5 JP 2021530536A5
Authority
JP
Japan
Prior art keywords
alkyl
group
cycloalkyl
disorder
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021502998A
Other languages
English (en)
Japanese (ja)
Other versions
JP7411631B2 (ja
JP2021530536A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/042703 external-priority patent/WO2020018970A1/en
Publication of JP2021530536A publication Critical patent/JP2021530536A/ja
Publication of JP2021530536A5 publication Critical patent/JP2021530536A5/ja
Application granted granted Critical
Publication of JP7411631B2 publication Critical patent/JP7411631B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021502998A 2018-07-20 2019-07-19 インターロイキン-1活性の阻害剤としてのスルホニル尿素化合物 Active JP7411631B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701358P 2018-07-20 2018-07-20
US62/701,358 2018-07-20
PCT/US2019/042703 WO2020018970A1 (en) 2018-07-20 2019-07-19 Sulfonylurea compounds as inhibitors of interleukin-1 activity

Publications (3)

Publication Number Publication Date
JP2021530536A JP2021530536A (ja) 2021-11-11
JP2021530536A5 true JP2021530536A5 (cg-RX-API-DMAC7.html) 2022-07-25
JP7411631B2 JP7411631B2 (ja) 2024-01-11

Family

ID=67515207

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021502998A Active JP7411631B2 (ja) 2018-07-20 2019-07-19 インターロイキン-1活性の阻害剤としてのスルホニル尿素化合物

Country Status (20)

Country Link
US (1) US11560391B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823726A1 (cg-RX-API-DMAC7.html)
JP (1) JP7411631B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210034588A (cg-RX-API-DMAC7.html)
CN (1) CN112437683A (cg-RX-API-DMAC7.html)
AR (1) AR117617A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019305095A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021001012A2 (cg-RX-API-DMAC7.html)
CA (1) CA3104199A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000152A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021000817A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210024A (cg-RX-API-DMAC7.html)
IL (1) IL280139A (cg-RX-API-DMAC7.html)
MA (1) MA53170A (cg-RX-API-DMAC7.html)
MX (1) MX2021000660A (cg-RX-API-DMAC7.html)
PE (1) PE20211049A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020552155A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202012159TA (cg-RX-API-DMAC7.html)
TW (1) TW202019937A (cg-RX-API-DMAC7.html)
WO (1) WO2020018970A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA126675C2 (uk) 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
CN114008030A (zh) 2019-06-21 2022-02-01 Ac免疫有限公司 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪
CA3158123A1 (en) * 2019-11-12 2021-05-20 Yonggang Wei Amide derivative and preparation method therefore and use thereof in medicine
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
US12624010B2 (en) 2020-06-19 2026-05-12 Ac Immune Sa Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway
JP2025502732A (ja) 2021-12-22 2025-01-28 エーシー・イミューン・エス・アー ジヒドロオキサゾール誘導体化合物
CA3252822A1 (en) 2022-02-21 2023-08-24 Viva Star Biosciences (Suzhou) Co., Ltd. NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INTERLEUKIN-1 ACTIVITY INHIBITORS
JP2025524640A (ja) 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Nlrp3インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
WO2024023266A1 (en) 2022-07-28 2024-02-01 Ac Immune Sa Novel compounds
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法
CN122555708A (zh) 2024-01-17 2026-08-11 Ac免疫有限公司 用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物
CN122555707A (zh) 2024-01-17 2026-08-11 Ac免疫有限公司 用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物
WO2025163069A1 (en) 2024-01-31 2025-08-07 Ac Immune Sa Novel compounds
WO2026132518A1 (en) 2024-12-20 2026-06-25 Ac Immune Sa Heterocyclic compounds modulating the nlrp3 inflammasome pathway

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216026A (en) 1990-07-17 1993-06-01 Eli Lilly And Company Antitumor compositions and methods of treatment
DK1270565T3 (da) 1997-01-29 2004-10-04 Pfizer 4-substitueret furan-2-sulfonamid og dets anvendelse i fremstillingen af sulfonylurinstofderivater
BR0014003A (pt) 1999-09-14 2002-05-21 Pfizer Prod Inc Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
AU2002341321A1 (en) 2001-11-30 2003-06-10 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
CA2789665C (en) * 2010-02-22 2020-06-16 Askat Inc. Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
TW201311693A (zh) 2011-09-02 2013-03-16 Kyowa Hakko Kirin Co Ltd 化學激活激素受體活性調節劑
JP6929792B2 (ja) 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
BR112018016671A2 (pt) 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
MA44729A (fr) 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
US11447460B2 (en) 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
UA126675C2 (uk) 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
CN110914256A (zh) 2017-07-07 2020-03-24 英夫拉索姆有限公司 新颖磺酰胺羧酰胺化合物
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
EP3668862A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
AU2018317800A1 (en) 2017-08-15 2020-02-13 Inflazome Limited Novel sulfonamide carboxamide compounds
TW201910314A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019092172A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
GB201803393D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
GB201803394D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
JP2021529780A (ja) 2018-07-03 2021-11-04 ノバルティス アーゲー Nlrp3アンタゴニストを使用するtnf阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
JP2021529187A (ja) 2018-07-03 2021-10-28 ノバルティス アーゲー Nlrpモジュレータ
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
AR117951A1 (es) 2018-07-20 2021-09-08 Gruenenthal Gmbh Derivados de triazolquinoxalina adicionalmente sustituidos
SG11202101480XA (en) 2018-08-15 2021-03-30 Inflazome Ltd Novel sulfonamideurea compounds
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
US20230011652A1 (en) 2018-10-24 2023-01-12 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
US20220227707A1 (en) 2019-01-22 2022-07-21 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
WO2021002887A1 (en) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Gut-targeted nlrp3 antagonists and their use in therapy

Similar Documents

Publication Publication Date Title
JP2021532101A5 (cg-RX-API-DMAC7.html)
HRP20211225T1 (hr) Sulfoniluree i srodni spojevi i njihova uporaba
JP2020505381A5 (cg-RX-API-DMAC7.html)
IL294536A (en) Sulfonimidamide compounds as nlrp3 modulators
TWI924849B (zh) 取代三嗪化合物
CN109803651B (zh) 免疫调节剂化合物
JP2020529405A5 (cg-RX-API-DMAC7.html)
HRP20220362T1 (hr) Biciklički kondenzirani heteroarilni ili arilni spojevi i njihova upotreba kao inhibitori irak4
JP6640222B2 (ja) ヘテロ環式誘導体およびその使用
JP2023531008A5 (cg-RX-API-DMAC7.html)
ME03822B (me) Natrijumova so n-((1 ,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1 h-pirazol- 3-sulfonamida
JP2020519596A5 (cg-RX-API-DMAC7.html)
JP2009533020A5 (cg-RX-API-DMAC7.html)
RU2008152443A (ru) Антитела высокой аффинности к il-6-рецептору человека
JP2022532812A5 (cg-RX-API-DMAC7.html)
TW201422638A (zh) 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
TW201233795A (en) Chemokine receptor binding polypeptides
JP2024534111A5 (cg-RX-API-DMAC7.html)
JP2017526731A5 (cg-RX-API-DMAC7.html)
JP2016517273A5 (cg-RX-API-DMAC7.html)
JP6876156B2 (ja) Il−17a及びil−17fに反応するモノクローナル抗体、及びその使用
JP2022536160A5 (cg-RX-API-DMAC7.html)
CN113943278B (zh) 一种免疫调节剂
JP2011518857A5 (cg-RX-API-DMAC7.html)
JP2023540733A5 (cg-RX-API-DMAC7.html)